Melting range was determined using Veego Melting Point VMP III apparatus.
The price range was determined using market testing which involved consulting with a core group of 20 investment institutions.
To further optimize the assay a signal range was determined using serial 10-fold dilutions of influenza A/WSN/33 virus.
The optimal inhibitor concentration range was determined using 10 μM, 30 μM and 50 μM on isolated WT MEFs, (Supplementary Figure 2a).
The precision in the low range was determined using an additional five native rabbit samples with previously measured (i.e. known) IGF-I concentrations.
The standard deviation (SD) of the assay over its working range was determined using 5 replicates of each serum amikacin concentrations of 0, 2.5, 5, 10, 20, and 40 μg/mL.
For each precipitation input model, the best performing parameter set and their associated uncertainty ranges were determined using the Sequential Uncertainty Fitting Procedure.
Population ranges were determined using J ± σ.
The "preferred" and "qualifying" property ranges were determined using internally developed programs.
